The study is a long-term extension, which means it follows people over a longer period after earlier treatment. During the trial, the medicine is taken by mouth and participants are watched over time for side effects and other health changes. Regular checkups and laboratory tests are used to follow general health, joint symptoms, and skin symptoms while treatment continues.

People in the study are assigned by chance to receive either tulisokibart or placebo, and neither the participants nor the study team knows which treatment is given during the study. Treatment is given over a period of time, and the main comparison is made after about 16 weeks. During the study, health checks are done to see how the disease and any side effects change over time.

The purpose of this study is to find out whether combining these two different biologic medications is safe and whether it works better at controlling disease activity than current treatments alone. The study will specifically measure how many patients achieve remission, which means their disease becomes much less active or shows minimal signs of inflammation. The researchers want to test whether blocking two different inflammation pathways at the same time can help more patients reach this state of very low disease activity.

During the study, patients will receive the combination treatment for a period of time while their disease activity is regularly monitored. The main assessment will take place at week 24 to see how well the combination therapy has worked. Throughout the study, doctors will also carefully watch for any side effects or safety concerns that might occur when using these two medications together. The study will collect information about how well patients tolerate the combination treatment and whether their symptoms improve according to standard measurement tools used to assess arthritis activity.

Participants in this research will receive different doses of the tablet form of JNJ-88545223 or a placebo. The study is randomized, meaning participants are assigned to a specific group by chance, and double-blind, which means neither the participants nor the researchers know which treatment is being given. This process is used to ensure the results are as objective as possible.

During the course of this research, participants will receive regular doses of the study drug to observe how it affects the body over an extended period. Medical professionals will monitor various aspects of health, including vital signs such as blood pressure and heart rate, as well as electrocardiogram results, which are tests that record the electrical activity of the heart. Additionally, regular blood tests will be performed to check hematology and clinical chemistry, which are used to examine the components of the blood and the chemical balance in the body.

During the study, participants will be randomly assigned to receive one of the treatments and will be followed for up to 52 weeks. The main focus at week 24 is to see how many people no longer have joint pain and show improvement in inflammation of the joints and tendons as measured by ultrasound imaging. Ultrasound is a type of scan that uses sound waves to create pictures of the inside of the body, allowing doctors to see inflammation in joints, tendons, and the areas where tendons attach to bone called entheses. The study will also track whether people develop full psoriatic arthritis by week 52, how well their skin psoriasis improves, and how their daily activities and quality of life are affected.

Throughout the study, doctors will use various measures to assess joint pain, skin symptoms, and inflammation. X-rays will be used to check for any changes in the joints over time. Participants will complete questionnaires about their pain, physical function, and how psoriasis and joint symptoms affect their daily life. The study will compare the effects of the different treatments to determine which approach is most effective in preventing or delaying the progression from early joint symptoms to full psoriatic arthritis while also treating the skin condition.

The purpose of this study is to see if SPY072 can reduce disease activity in people with these three types of rheumatologic disease and to check if the medication is safe. The study will measure how well SPY072 works by looking at different aspects of disease activity. For rheumatoid arthritis, the study will check changes in disease activity at week 12. For axial spondyloarthritis and psoriatic arthritis, measurements will be taken at week 16. The study will also look at how many participants show improvement in their symptoms and will measure the levels of the medication in the blood.

During the study, participants will receive treatment for up to 40 weeks. The study will monitor participants for any unwanted effects or problems that might occur with the medication. The study will also check if the body develops any immune response to the medication. Different measurements will be used depending on which type of rheumatologic disease the participant has, but all are designed to see if the medication helps reduce joint pain, swelling, and other symptoms of the disease.

The purpose of this research is to determine if gradually reducing the dose of these medications is as effective as continuing with the current dose in patients whose disease is well-controlled. The study will examine patients who have maintained low disease activity or whose symptoms have been in remission for at least 6 months while taking these medications.

During the 12-month study period, participants will be monitored for disease activity, quality of life, and any side effects. The study will track how well the joints function, any disease flare-ups, and other health-related factors. Researchers will also measure medication levels in the blood and examine immune system cells to better understand how these treatments work.

The study will collect breast milk samples from mothers who are already receiving bimekizumab treatment as prescribed by their doctor. Samples will be taken over a period of two weeks, with additional samples collected depending on how often the participant receives their medication. The main purpose is to measure the amount of medication that passes into breast milk.

Participants must be at least 18 years old, currently breastfeeding, and have been receiving bimekizumab treatment for at least 12 weeks after giving birth. The study will monitor both mothers and infants for any side effects throughout the study period. The medication dose and schedule will continue as previously prescribed by the participant’s doctor.

Two different RSV vaccines will be used in the study: Arexvy and Abrysvo. Both vaccines are given as a single injection into the muscle. The purpose is to determine if the medications used to treat inflammatory rheumatic disease affect how well the body develops protection after receiving the RSV vaccine.

Participants will receive one dose of the RSV vaccine and will have blood samples taken before and after vaccination to measure their body’s immune response. The study will also monitor any side effects that may occur after vaccination. This information will help healthcare providers better understand how these treatments influence vaccine effectiveness in patients with inflammatory rheumatic disease.

During the study, participants with active arthritis who are currently using TNF inhibitors will receive a combination therapy approach. The research will monitor how well this combination works to reduce disease activity and inflammation in the joints. The main goal is to see if patients can achieve remission, which means having very low or no disease activity after 24 weeks of treatment.

The study will also collect information about the safety and tolerability of combining these medications. This approach using multiple medications together is being investigated as a potential way to improve outcomes for patients whose arthritis symptoms aren’t adequately controlled with current therapies.

The purpose of the study is to evaluate how well these medications work when used together and separately in treating active psoriatic arthritis. Participants will receive either the combination of both medications, one of the medications alone, or a placebo. The study will monitor the participants over a period to see how their symptoms change and to ensure the treatments are safe and well-tolerated.

Throughout the study, participants will have regular check-ups to assess their response to the treatment. The main goal is to see if there is a significant improvement in joint symptoms and overall disease activity. The study will also look at the safety of the treatments to ensure they do not cause any harmful effects. This research aims to find more effective ways to manage psoriatic arthritis and improve the quality of life for those affected by this condition.

Participants in the study will receive Ixekizumab and will be monitored over a period of time to see how their condition changes. The study will look at how the treatment affects the joints and overall symptoms of the disease. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The main goal is to see if the treatment helps reduce the symptoms of psoriatic arthritis after 12 weeks.

Throughout the study, various tests and assessments will be conducted to measure the response to the treatment. These include checking the number of swollen and tender joints, as well as using imaging techniques to look at the joints. The study will also evaluate other aspects of the disease, such as pain levels and physical function, to get a comprehensive understanding of how Ixekizumab works in treating psoriatic arthritis.

The purpose of the study is to evaluate how well Upadacitinib can reduce symptoms such as inflammation and pain in the spine and joints of patients with active symptoms of these conditions. Participants will take the medication or placebo orally in the form of a modified-release tablet. The study will last for a period of 24 weeks, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI (Magnetic Resonance Imaging), to measure inflammation in the spine and joints. The study aims to provide valuable information on the effectiveness of Upadacitinib in managing symptoms of Psoriatic Arthritis and Axial Spondyloarthritis, potentially offering a new treatment option for individuals affected by these conditions.

The purpose of the study is to understand how bimekizumab affects certain biological markers in the body, which are indicators of how the disease is behaving. Participants will receive the treatment over a period of time, and the study will observe changes in these markers at different points, particularly at Week 48. The study will also monitor any side effects that may occur during the treatment period.

Participants will be asked to provide skin samples to help researchers analyze the effects of the medication on gene expression, which is the process by which information from a gene is used to create proteins that affect cell function. This study aims to provide insights into how bimekizumab works in treating these conditions and to gather information on its safety and effectiveness.

The study will be conducted over a period of time, during which participants will take the medication in the form of a film-coated tablet. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The study will also consider the participants’ previous use of biologic treatments, which are advanced medications used to treat psoriatic arthritis.

Throughout the study, participants will be monitored to assess the medication’s impact on their condition. This includes looking at improvements in joint tenderness and swelling, as well as skin symptoms associated with psoriasis. The study will also evaluate changes in participants’ overall health and quality of life. The goal is to determine if zasocitinib can provide significant relief from the symptoms of psoriatic arthritis compared to the placebo. The study is expected to continue until 2028, with recruitment starting in 2025.

Participants in the study will be randomly assigned to receive either zasocitinib, a matching placebo, or another active treatment. A placebo is a substance with no active medication, used to compare the effects of the actual drug. The study will last for up to 52 weeks, during which participants will take the medication in the form of film-coated tablets. The goal is to see if zasocitinib can improve the symptoms of Psoriatic Arthritis, such as joint pain and swelling, compared to the placebo and other treatments.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. The study will assess various outcomes, including improvements in joint symptoms and overall quality of life. This research is important for understanding how zasocitinib can help people with Psoriatic Arthritis and potentially offer a new treatment option for those affected by this condition.

The purpose of this study is to evaluate how well ixekizumab works compared to methotrexate in treating a specific symptom of psoriatic arthritis called dactylitis, which is the swelling of fingers or toes. Participants in the study will receive either ixekizumab or methotrexate as a monotherapy, meaning they will not be combined with other treatments. The study will use a scoring system called the DACTOS score to measure the response to treatment, along with ultrasound assessments to observe changes in the affected areas.

The study will take place over a period of time, with participants receiving their assigned treatment and undergoing regular assessments to monitor their progress. The goal is to determine which treatment is more effective in reducing the symptoms of dactylitis in people with psoriatic arthritis. This information will help improve treatment options for individuals living with this condition.

The purpose of the study is to evaluate how well JNJ-77242113 works in reducing the signs and symptoms of psoriatic arthritis in people who have previously been treated with other biological medications. The study will last for several weeks, during which participants will take the medication and have regular check-ups to monitor their condition and any changes in their symptoms.

Participants will be randomly assigned to receive either the active medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study, which helps ensure that the results are not biased. The main goal is to see if the medication can help improve the condition by Week 16, as measured by a standard response used in rheumatology studies.

The purpose of the study is to assess how effective and safe JNJ-77242113 is in reducing the signs and symptoms of psoriatic arthritis. The study will compare the effects of this medication to a placebo, which is a substance with no active drug. Participants will receive either the medication or the placebo and will be monitored over a period of time to see how their symptoms change.

During the study, participants will receive the treatment for up to 100 weeks. The medication will be administered in different doses, and the effects will be evaluated at various points, including at 16 weeks. The study aims to provide valuable information on whether JNJ-77242113 can be a beneficial treatment option for those suffering from active psoriatic arthritis.

Participants in the study will receive Sonelokimab through a subcutaneous injection, which means it is injected under the skin. Additionally, a special imaging agent called 68Ga-FAPI-46 will be used to help visualize the inflammation in the body. This agent is injected and then detected using a scan called FAPI-PET/CT, which combines positron emission tomography and low-dose computed tomography to create detailed images of the body’s internal structures.

The purpose of the study is to assess changes in disease activity over a period of 12 weeks. Participants will undergo regular imaging scans to monitor the effects of the treatment. The study will help researchers understand how Sonelokimab impacts inflammation in the joints and spine, potentially leading to better treatment options for people with these conditions.

During the study, participants will receive either sonelokimab at different doses, risankizumab, or placebo through subcutaneous injection. The medications work by targeting specific proteins in the body that cause inflammation. The main focus will be on checking if sonelokimab helps reduce joint symptoms after 16 weeks of treatment.

The study will monitor how the medications affect both joint pain and skin symptoms associated with psoriatic arthritis. Participants will have regular check-ups to assess their response to treatment and to monitor their overall health. The medications being tested are designed to help reduce inflammation and improve symptoms in people whose condition has not improved enough with other treatments called TNF-alpha inhibitors.

The purpose of this research is to determine how well sonelokimab works compared to placebo in treating people with active psoriatic arthritis who have not previously used biological medications. The study will compare two different ways of giving sonelokimab against placebo treatment.

Participants will receive either sonelokimab injections or placebo for 16 weeks. The medication dose will be 60 milligrams, given every four weeks. Throughout the study, doctors will monitor the participants’ symptoms, particularly focusing on how their joint pain and inflammation respond to the treatment. The study will also track any changes in participants’ ability to perform daily activities and their overall well-being.

The purpose of the study is to evaluate how effective guselkumab is in improving the signs and symptoms of psoriatic arthritis and to see if it can help slow down the damage to the joints that can be seen on X-rays. Participants in the study will receive either guselkumab or a placebo, which looks like the medication but does not contain the active ingredient. The study will follow participants over a period of time to monitor their response to the treatment.

Throughout the study, participants will receive regular injections and attend scheduled visits to check on their progress. The study aims to provide valuable information on whether guselkumab can be a safe and effective treatment option for people living with active psoriatic arthritis.

The purpose of this study is to investigate how safe the Shingrix vaccine is for people with these conditions and how it affects their disease activity. Participants in the study will receive the vaccine and be monitored over a period of time to see if there are any changes in their Psoriasis or Psoriatic Arthritis symptoms. The study will also look at how well the immune system responds to the vaccine by measuring certain immune markers in the blood.

Throughout the study, participants will receive two doses of the Shingrix vaccine, given as an injection into the muscle. They will be observed for any side effects, such as reactions at the injection site or other health changes. The study will last for about a year, with regular check-ups to ensure the safety and effectiveness of the vaccine. Participants will also be checked for any signs of shingles or related complications during the study period.

The purpose of the study is to compare the effectiveness of taking tofacitinib either in the morning or in the evening. Participants will be randomly assigned to take the medication at one of these times. The study will last for about three months, during which participants will report on their disease activity, which refers to how active their arthritis symptoms are. The study will also look at other factors like morning stiffness, general health, fatigue, pain, sleep, and quality of life.

Researchers will also explore whether changes in certain genes related to the body’s internal clock, known as circadian clock genes, and the composition of bacteria in the gut, called microbiota, are linked to how well the treatment works. This study aims to provide insights into the best time of day to take tofacitinib for managing symptoms of rheumatoid arthritis and psoriatic arthritis.

The purpose of the study is to evaluate how well Risankizumab works in reducing the signs and symptoms of Psoriatic Arthritis. Participants in the study will receive either Risankizumab or a placebo through injections. The study will monitor the participants over a period of time to assess improvements in their condition. The main goal is to see if participants achieve a significant reduction in their symptoms by the 24th week of the study.

Throughout the study, various health assessments will be conducted to measure changes in the participants’ condition. These assessments will help determine the effectiveness of Risankizumab in managing Psoriatic Arthritis symptoms. The study aims to provide valuable information on whether Risankizumab can be a beneficial treatment option for individuals with this condition, especially for those who have not responded well to other treatments in the past.

The purpose of the study is to evaluate the effectiveness of Risankizumab in reducing the signs and symptoms of Psoriatic Arthritis in participants who have not responded well to or cannot tolerate at least one previous treatment known as a Disease Modifying Anti-Rheumatic Drug (DMARD). Participants will receive either Risankizumab or a placebo, and the study will monitor their progress over a period of time to assess improvements in their condition.

Throughout the study, participants will receive regular injections and attend scheduled visits to track their health and any changes in their symptoms. The study aims to determine if Risankizumab can provide significant relief from the symptoms of Psoriatic Arthritis compared to the placebo. The trial is designed to ensure that all participants are closely monitored for safety and effectiveness of the treatment.

The purpose of this study is to understand how Upadacitinib affects pain processing in the brain of people with Psoriatic Arthritis. This is done by observing changes in brain activity using a method called fMRI, which stands for functional magnetic resonance imaging. This imaging technique helps researchers see how different parts of the brain respond to the medication over time.

Participants in the study will take Upadacitinib and have their brain activity monitored at different points during the study. The study will last for several weeks, and participants will have regular check-ups to monitor their progress and any changes in their condition. The goal is to gather information on how the medication affects pain and brain activity in the short and long term.

The purpose of the study is to evaluate how well tofacitinib can help patients achieve and maintain remission, which means a period where symptoms are reduced or disappear. The study will also look at how patients do after stopping the medication. Participants in the study will take tofacitinib and will be monitored over a period of time to see how their condition changes. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active ingredient.

Throughout the study, participants will have regular check-ups to assess their symptoms and overall health. The study will track the number of patients who reach remission at different points, such as 24 weeks, and will also look at how long patients can stay in remission without medication. The study aims to provide valuable information on the effectiveness of tofacitinib in managing Psoriatic Arthritis and improving the quality of life for those affected by this condition.

The purpose of this research is to examine how ixekizumab affects inflammation throughout the entire body, including joints and areas where tendons and ligaments attach to bones. The medication will be administered as a solution for injection, with participants receiving up to 160 mg per day. The study will use special imaging techniques including MRI (magnetic resonance imaging) and CT (computed tomography) scans to monitor the effects of treatment.

The study will last for two years, during which participants will receive regular medical evaluations and imaging scans. The research will help understand how effectively the medication reduces inflammation in different parts of the body in people with these conditions. Throughout the study, doctors will monitor how the treatment affects both the spine and other joints in the body.

The purpose of this study is to evaluate how effective Guselkumab is in reducing the signs and symptoms of Psoriatic Arthritis. Participants will receive Guselkumab through an injection under the skin, using a pre-filled syringe. Some participants will receive a placebo, which looks like the medication but does not contain the active ingredient. The study will compare the effects of Guselkumab to the placebo to determine its effectiveness.

Throughout the study, participants will be monitored to assess their response to the treatment. The main goal is to see how many participants achieve a significant improvement in their condition by the 24th week of the study. This improvement is measured by a standard response called ACR 20, which indicates a 20% improvement in the number of tender and swollen joints, as well as other criteria related to Psoriatic Arthritis. The study aims to provide valuable information on the safety and benefits of using Guselkumab for treating this condition.

The purpose of this study is to assess how well Guselkumab can reduce symptoms related to the axial part of Psoriatic Arthritis. Participants in the study will receive either Guselkumab or a placebo through subcutaneous injections, which means the medication is injected under the skin. The study will follow participants over a period of time to observe changes in their symptoms and overall health. The main focus will be on the reduction of symptoms such as spinal pain and inflammation, which are common in individuals with this condition.

Throughout the study, participants will be monitored to ensure their safety and to gather data on the effectiveness of the treatment. The study aims to provide valuable information on whether Guselkumab can be a beneficial treatment option for those suffering from Psoriatic Arthritis with axial involvement. This research is important as it seeks to improve the quality of life for individuals affected by this chronic condition.

Participants in the study will receive either Tildrakizumab or a placebo, which looks like the treatment but does not contain the active medicine. The study will last for 24 weeks, during which time participants will receive regular injections and have their health monitored by the study team. The main goal is to see if participants experience a 20% improvement in their symptoms by the end of the study period.

Throughout the study, the safety and tolerability of Tildrakizumab will be closely observed to ensure that it is safe for use in treating Psoriatic Arthritis. Participants will have regular check-ups to monitor their progress and any potential side effects. This study aims to provide valuable information on the effectiveness of Tildrakizumab for individuals with this condition.

The study will involve patients who have not previously been treated with a type of medication known as bDMARDs, which are biologic disease-modifying antirheumatic drugs. Participants will receive Guselkumab injections over a period of up to 52 weeks. The main goal is to observe whether the enthesitis resolves by week 24 of the study. Enthesitis is confirmed using ultrasound, a technique that uses sound waves to create images of the inside of the body, helping to identify inflammation.

This trial is open-label, meaning both the researchers and participants know which treatment is being administered. The study will not use a placebo, and all participants will receive the active medication, Guselkumab. The trial aims to provide valuable information on the effectiveness of Guselkumab in treating enthesitis in patients with Psoriatic Arthritis, potentially offering a new treatment option for those affected by this condition.

Participants in the study will be divided into groups based on their previous treatment history. Some participants may have used medications like methotrexate, sulfasalazine, or leflunomide, while others may not have used these treatments before. The study will last for a period of 16 weeks, during which participants will receive either tofacitinib or a placebo. The researchers will collect various types of data, including clinical, molecular, and imaging information, to understand how these factors might influence the effectiveness of tofacitinib in treating psoriatic arthritis.

The main goal is to see if participants achieve what is known as Minimal Disease Activity by the end of the study. This means that the symptoms of psoriatic arthritis are significantly reduced. The study will also look at changes in certain clinical scores and molecular profiles before and after treatment. This research aims to improve understanding of how tofacitinib works and to help doctors predict which patients are most likely to benefit from this treatment.

The purpose of the study is to evaluate the effectiveness and safety of Tildrakizumab in people with active Psoriatic Arthritis. Participants in the study will receive either Tildrakizumab or a placebo and will be monitored over a period of 24 weeks. During this time, researchers will assess how many participants experience a 20% improvement in their symptoms, as well as monitor any side effects.

This study aims to provide valuable information about the potential benefits and risks of using Tildrakizumab for treating Psoriatic Arthritis. By participating, individuals will contribute to research that could lead to better treatment options for this condition in the future.

The purpose of the study is to assess how safe and tolerable bimekizumab is when used over an extended period. Participants in the study will receive regular injections of bimekizumab and will be monitored to see how their condition responds to the treatment. The study will also track any side effects that may occur during the treatment period.

Throughout the study, participants will have regular check-ups to evaluate their health and the effectiveness of the treatment. The study aims to provide valuable information on the long-term use of bimekizumab for managing Psoriatic Arthritis, helping to determine if it is a safe and effective option for patients with this condition.

The purpose of the study is to evaluate how far these medications can be reduced without causing a return of symptoms. Participants will be randomly assigned to different treatment groups, and the study will last for up to 24 months. During this time, the participants’ health will be closely monitored to ensure that their condition remains stable. The study will involve regular check-ups to assess the activity of the disease and the overall health and quality of life of the participants.

Throughout the study, participants will receive either the medication or a placebo, and their progress will be tracked to see if they can maintain minimal disease activity. The study will help determine the best approach to managing psoriatic arthritis with the least amount of medication necessary, aiming to improve the quality of life for those affected by this condition.

The purpose of the study is to evaluate how well deucravacitinib works in treating active psoriatic arthritis. Participants will receive either deucravacitinib or a placebo, and the study will monitor their progress over a period of time. The medication is taken orally in the form of film-coated tablets. The study will assess various health outcomes, including improvements in joint pain and skin symptoms, over several weeks.

Throughout the study, participants will be regularly checked to see how their condition is responding to the treatment. The study aims to provide valuable information on whether deucravacitinib can be an effective treatment option for people with psoriatic arthritis, potentially offering relief from the symptoms associated with this condition.